Valeant Pharmaceuticals Intl I - VRX - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Valeant Pharmaceuticals Intl I - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
VRX	New York	2834	http://www.valeant.com	84.82 +0.62
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Valeant Pharmaceuticals Intl I 4 Healthcare Stock Stories Making Waves On Monday - Jun 17th, 2013 4:46 pm Valeant Pharma plans $1.75B stock offering - Jun 17th, 2013 2:53 pm Valeant Pharma plans $1.75B stock offering - Jun 17th, 2013 2:53 pm After-Hours Buzz: Korn/Ferry, Host Hotels, Campbell Soup & More - Jun 17th, 2013 2:47 pm InPlay: Valeant Pharma announces public offering of common shares to raise gross proceeds of ~$1.75 bln - Jun 17th, 2013 2:02 pm Valeant Pharmaceuticals Announces Public Offering Of Common Shares - Jun 17th, 2013 2:02 pm Valeant Pharmaceuticals Announces Public Offering Of Common Shares - Jun 17th, 2013 2:02 pm Monday 6/17 Insider Buying Report: STRA, VRX - Jun 17th, 2013 8:50 am VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits - Jun 16th, 2013 11:16 pm Top Buys by Top Brass: EVP Kornwasser's $141.2K Bet on VRX - Jun 14th, 2013 10:23 am Warner Chilcott: Should You Buy Joel Greenblatt's Latest Pick? - Jun 14th, 2013 9:34 am Valeant Biting More Than it Can Chew - Jun 14th, 2013 8:32 am Tme to Buy This Defensive Growth Stock? - Jun 12th, 2013 5:45 am Valeant Pharmaceuticals International, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 09:20 AM - Jun 11th, 2013 5:50 pm This Company is Set for Newer Heights in the Eye-Care Sector - Jun 11th, 2013 2:22 pm Charting a resilient bull market - Jun 11th, 2013 9:56 am Big Cap 20 Outperforming S&P 500, IBD 50 Too - Jun 10th, 2013 4:08 pm Hyperion Acquires Buphenyl Rights - Jun 10th, 2013 2:35 pm Tax leverage helps make Irish pharma a popular target - Jun 10th, 2013 12:58 pm DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower - Jun 10th, 2013 11:03 am View All Current Headlines >>